2025 Global Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report
Description
The 2025 Global Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Alzheimer's Disease Diagnostic Market globally include F. Hoffmann-La Roche AG, Eli Lilly and Company, Quest Diagnostics, and ALZpath, Inc. F. Hoffmann-La Roche is a leading player, focusing on developing advanced diagnostic tools, including blood-based biomarkers for early Alzheimer's detection. Eli Lilly and Company is noted for its strong presence, with investments in diagnostic and therapeutic innovations, often collaborating on cutting-edge Alzheimer’s diagnostics. Quest Diagnostics offers novel laboratory blood tests supporting amyloid brain pathology detection and is expanding diagnostic capabilities worldwide. ALZpath, recently named to Fast Company’s Most Innovative list in 2025, specializes in proprietary pTau217 antibody technology enabling highly sensitive, early-stage blood tests for Alzheimer's diagnosis, with global partnerships to broaden access.
These companies leverage innovative technologies such as blood-based biomarkers, AI integration for enhanced diagnostic accuracy, and advanced imaging techniques like PET and MRI. Roche and Quest Diagnostics focus on broad clinical application and regulatory approvals, while ALZpath provides critical antibodies licensed to industry leaders like Roche and Beckman Coulter, whose assays have FDA breakthrough designations aiming at accelerated clinical use. Eli Lilly and Biogen collaborate on therapeutic compounds with diagnostic utility, aligning with their market influence. The global market, valued at approximately USD 9.94 billion in 2025, is rapidly growing due to increased awareness, early screening demands, and supportive innovation ecosystems, with North America and Asia-Pacific being key regions.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Alzheimer's Disease Diagnostic Market globally include F. Hoffmann-La Roche AG, Eli Lilly and Company, Quest Diagnostics, and ALZpath, Inc. F. Hoffmann-La Roche is a leading player, focusing on developing advanced diagnostic tools, including blood-based biomarkers for early Alzheimer's detection. Eli Lilly and Company is noted for its strong presence, with investments in diagnostic and therapeutic innovations, often collaborating on cutting-edge Alzheimer’s diagnostics. Quest Diagnostics offers novel laboratory blood tests supporting amyloid brain pathology detection and is expanding diagnostic capabilities worldwide. ALZpath, recently named to Fast Company’s Most Innovative list in 2025, specializes in proprietary pTau217 antibody technology enabling highly sensitive, early-stage blood tests for Alzheimer's diagnosis, with global partnerships to broaden access.
These companies leverage innovative technologies such as blood-based biomarkers, AI integration for enhanced diagnostic accuracy, and advanced imaging techniques like PET and MRI. Roche and Quest Diagnostics focus on broad clinical application and regulatory approvals, while ALZpath provides critical antibodies licensed to industry leaders like Roche and Beckman Coulter, whose assays have FDA breakthrough designations aiming at accelerated clinical use. Eli Lilly and Biogen collaborate on therapeutic compounds with diagnostic utility, aligning with their market influence. The global market, valued at approximately USD 9.94 billion in 2025, is rapidly growing due to increased awareness, early screening demands, and supportive innovation ecosystems, with North America and Asia-Pacific being key regions.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
